Program to reduce cardiovascular disease risk in psoriasis patients
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis: Translating Guidelines of Care to Better Outcomes for Patients With Psoriatic Disease
This study tests a new program that helps people with psoriasis and psoriatic arthritis lower their risk of heart disease by managing key health factors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 520 (estimated) |
| Ages | 40 Years to 75 Years |
| Sex | All |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 10 sites (Fort Smith, Arkansas and 9 other locations) |
| Trial ID | NCT05908240 on ClinicalTrials.gov |
What this trial studies
This research aims to evaluate a centralized care coordinator program designed to help patients with psoriasis and psoriatic arthritis lower their risk of cardiovascular disease. The program focuses on managing modifiable cardiovascular risk factors through standard care approaches. By integrating care coordinators into the treatment process, the study seeks to improve health outcomes for patients who may not have their cardiovascular risks adequately addressed. The intervention will be tested in various clinical settings to assess its effectiveness.
Who should consider this trial
Good fit: Ideal candidates for this study are males and females aged 40-75 who are receiving routine care for psoriasis.
Not a fit: Patients currently taking prescription lipid-lowering medications or those with a known history of cardiovascular disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly reduce the risk of cardiovascular disease and mortality in patients with psoriasis and psoriatic arthritis.
How similar studies have performed: Previous studies have shown that care coordinators can improve outcomes in patients with chronic diseases, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Willing and able to provide informed consent 2. Male or female aged 40-75 3. Being seen by a dermatology provider in routine care for the primary encounter diagnosis of psoriasis Exclusion Criteria: 1. Currently taking a prescription lipid lowering medication 2. Pregnant or planning pregnancy in the next 6 months 3. Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)
Where this trial is running
Fort Smith, Arkansas and 9 other locations
- Johnson Dermatology — Fort Smith, Arkansas, United States (Recruiting)
- Dawes Fretzin Clinical Research — Columbus, Indiana, United States (Recruiting)
- Dawes Fretzin Clinical Research — Indianapolis, Indiana, United States (Recruiting)
- MiSkinCenter — Northville, Michigan, United States (Recruiting)
- SUNY Downstate — Brooklyn, New York, United States (Recruiting)
- City Dermatology — Bensalem, Pennsylvania, United States (Recruiting)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
- University of Utah — Salt Lake City, Utah, United States (Recruiting)
- University of Virginia — Charlottesville, Virginia, United States (Recruiting)
- Bellevue Dermatology Clinic — Bellevue, Washington, United States (Recruiting)
Study contacts
- Study coordinator: Brooke Bishop, MPH
- Email: Brooke.Bishop@pennmedicine.upenn.edu
- Phone: 267-581-9714
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.